Malignant Neoplasms
|
0.400 |
CausalMutation
|
group |
CGI |
|
|
|
Malignant Neoplasms
|
0.400 |
GenomicAlterations
|
group |
CGI |
|
|
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer.
|
30463996 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
(111)In-labeled trastuzumab modified with nuclear localizing signal (NLS) peptides ((111)In-trastuzumab-NLS) efficiently delivers an Auger electron (AE) emitter (111)In into the cell nucleus and is thus a promising radiopharmaceutical in AE radioimmunotherapy (AE-RIT) for targeted killing of HER2-positive cancer.
|
26447839 |
2015 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
111In-benzyl-DOTA-Z(HER2:342) has a potential for imaging of HER2 expression in malignant tumors.
|
17671747 |
2007 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
76 cancer genes were found to be significantly altered with several as potential copy number drivers, including ERBB2 in mucinous, and TPM3 in endometrioid histotypes.
|
23078675 |
2012 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
9 of 71 (13%) cases of lobular cancer featured HER-2/neu gene amplification, whereas 51 (48%) of 106 cases of ductal cancer showed amplification (P < 0.0001).
|
11893034 |
2002 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Cancer stem/progenitor cells are less polyploid than cancer cells in general and may not be HER2/neu amplified.
|
19838757 |
2010 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Cancer cells generally expressed HER2 at higher levels than that found in normal ovarian surface epithelial (OSE) cells.
|
23189165 |
2012 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.
|
26285240 |
2015 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
|
26474458 |
2015 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Cancer biopsy were obtained from 21 untreated HER2 negative advanced GC patients, retrospectively analyzed.
|
26793992 |
2016 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Cancer site, specimen type (endoscopic biopsy/resection/metastases), immunohistochemistry (IHC) score, HER2 gene and CEP17 copy number (CN) and HER2:CEP17 ratios were recorded.
|
28823752 |
2017 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Cancer specific survival (CSS) was impaired in patients with high gene expression of Her2 (P=0.0009) and ESR1 (P=0.04).
|
29477637 |
2018 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
HER-2/neu is overexpressed in most epithelial malignancies.
|
11236029 |
2000 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
ErbB2 is overexpressed in many different cancers and has been linked to enhanced malignancy of tumors.
|
11796827 |
2002 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
ErbB2 and alpha6 integrin have been implicated in malignancy of breast cancer cells.
|
12584562 |
2003 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
ErbB2 and EGFR are attractive oncology therapeutic targets as their overexpression in tumors predicts a poorer clinical outcome in a variety of epithelial malignancies.
|
15305194 |
2004 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
HER-2/neu oncogene activation by either gene amplification and/or protein overexpression has been documented in several human malignancies.
|
15386424 |
2005 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
HER-2 is a proto-oncogene that has an important role in many human cancers, including Pca.
|
15389808 |
2005 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, Her-2-neu) gene amplification and overexpression has been reported in several types of cancer.
|
15511476 |
2004 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies.
|
15547690 |
2004 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
HER2/neu was found to be significantly overexpressed in the malignant group compared to the benign and normal groups (P < 0.001) and no significant difference was found between the bilharzial and nonbilharzial cancer groups or between the transitional and squamous cell carcinoma groups.
|
15642276 |
2005 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
HER-2/neu protein is a transmembrane tyrosine kinase cell surface growth factor receptor that is expressed on normal epithelial and some cancer cells.
|
15816639 |
2005 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Her 2/neu gene amplification has been reported in several types of cancer.
|
16303179 |
2006 |